Listar por autor "Oliver-Martos, Begoña"
Mostrando ítems 21-32 de 32
-
NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients
Malhotra, Sunny; Costa, Carme; Eixarch, Herena; Keller, Christian W; Lukas Amman, Lukas; Martínez-Banaclocha, Helios; Midaglia, Luciana; Sarró, Eduard; Isabel Machín-Díaz, Isabel; M Villar, Luisa; Triviño, Juan Carlos; Oliver-Martos, Begoña
; Navarro Parladé, Laura; Calvo-Barreiro, Laura; Matesanz, Fuencisla; Vandenbroeck, Koen; Urcelay, Elena; María-Luisa Martínez-Ginés, María-Luisa; Tejeda-Velarde, Amalia; Fissolo, Nicolás; Castilló, Joaquín; Sanchez, Alex; Robertson, Avril A B; Clemente, Diego; Prinz, Marco; Pelegrin, Pablo; Lünemann, Jan D; Espejo, Carmen; Montalban, Xavier; Comabella, Manuel[et al.] (Oxford Academic, 2020)
Primary progressive multiple sclerosis is a poorly understood disease entity with no specific prognostic biomarkers and scarce therapeutic options. We aimed to identify disease activity biomarkers in multiple sclerosis by ... -
NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis
Malhotra, Sunny; Rio, Jordi; Urcelay, Elena; Nurtdinov, Ramil; F Bustamante, Marta; Fernández Fernández, Óscar; Oliver-Martos, Begoña; Zettl, Uwe; Brassat, David; Killestein, Joep; Lechner-Scott, Jeannette; Drulovic, Jelena; Chan, Andrew; Martinelli-Boneschi, Filippo; García-Merino, Antonio; Montalban, Xavier; Comabella, Manuel[et al.] (2015)
-
Perfiles de expresión génica y perfiles de activación de la vía JAK-STAT asociados a la respuesta al tratamiento con IFNβ en pacientes con esclerosis múltiple.
(UMA Editorial, 2017-07-13)En la actualidad, aunque existen numerosos fármacos disponibles para el tratamiento de la esclerosis múltiple (EM), el interferón beta (IFNß) continúa siendo un tratamiento ampliamente utilizado por su excelente relación ... -
Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
Requena-Ocaña, Nerea; Araos Gómez, Pedro Fernando; Serrano-Castro, Pedro Jesús; Flores-López, María; García-Marchena, Nuria; Oliver-Martos, Begoña; Ruiz-Ruiz, Juan Jesús; Gavito, Ana L.; Pavón-Morón, Francisco Javier; Serrano, Antonia; Mayoral Cleries, Fermín; Suárez-Pérez, Juan; Rodriguez-de-Fonseca, Fernando[et al.] (IOAP-MDPI, 2023-01-07)
For a long time, Substance Use Disorders (SUDs) were not considered a component in the etiology of dementia. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders introduced substance-induced ... -
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis.
Ciano-Petersen, Nicolas Lundahl; Mélisse, Robert; Muñiz-Castrillo, Sergio; Wucher, Valentin; Klich, Amna; Alberto Vogrig, Alberto; Villagrán García, Macarena; Antonio Farina, Antonio; David Goncalves, David; Geraldine Picard, Geraldine; Veronique Rogemond, Veronique; Bastien Joubert, Bastien; Oliver-Martos, Begoña; Serrano-Castro, Pedro Jesús; Maucort-Boulch, Delphine; Honnorat, Jerome[et al.] (American Academy of Neurology, 2023-05-05)
Background and objectives: Anti-NMDA receptor (NMDAR) encephalitis is defined by the presence of antibodies (Abs) targeting the NMDAR in the CSF. This study aimed to determine the prognostic value of persistent CSF NMDAR-Abs ... -
Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis
Suardíaz García, Margarita; Clemente, Diego; Marín Bañasco, Carmen; Órpez, Teresa; Hurtado-Guerrero, Isaac; Pavía-Molina, José; Pinto-Medel, Maria Jesús; De Castro, Fernando; Leyva-Fernández, Laura; Fernández Fernández, Óscar; Oliver-Martos, Begoña[et al.] (Elsevier, 2016)
Endogenous interferon beta (IFNβ) is an important cytokine involved in several chronic inflammatory diseases, such as Multiple Sclerosis (MS). In spite of the numerous therapeutic approaches available for MS patients, the ... -
Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy
Aliaga-Gaspar, Pablo; Brichette-Mieg, Isabel; Fernández-Arjona, María del Mar; Rodríguez-Bada, José Luis; Lopez-Moreno, Yolanda; Serrano-Castro, Pedro Jesús; Fernández Fernández, Oscar; Ciano-Petersen, Nicolas Lundahl; Oliver-Martos, Begoña[et al.] (Elsevier, 2024)
The soluble type I IFN receptor (sIFNAR2) is produced by alternative splicing and is present in body fluids. Although it can modulate IFN-ß activity, its biological role remains unknown. Methods: An in-silico study was ... -
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
Aliaga-Gaspar, Pablo; Hurtado-Guerrero, Isaac; Ciano-Petersen, Nicolas Lundahl; Urbaneja, Patricia; Brichette Mieg, Isabel; Virginia Reyes, Virginia; Rodríguez-Bada, José Luis; Alvarez-Lafuente, Roberto; Arroyo, Rafael; Quintana, Ester; Ramió-Torrentà, Lluis; Alonso, Ana; Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (2021-12)
Protein and mRNA levels of sIFNAR2 increased after IFN-b treatment. According to the clinical response, only non-responders increased sIFNAR2 significantly at both protein and mRNA levels. sIFNAR2 gene expression correlated ... -
The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis.
Pinto-Medel, María Jesús; García-León, Juan Antonio; Oliver-Martos, Begoña; López-Gómez, Carlos; Luque, Gloria; Arnáiz-Urrutia, Carlos; Órpez, Teresa; Marín-Bañasco, Carmen; Fernández Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2012-01-18)
Multiple sclerosis (MS) is a chronic debilitating disease, in which T-cells are considered to play a pivotal role. CD28 is the quintessential costimulatory molecule on T-cells and its expression declines progressively ... -
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández Fernández, Óscar; Papais Alvarenga, Marcos; Guerrero, Miguel; León, Antonio; Alonso, Ana; López-Madrona, Jose Carlos; Leyva-Fernández, Laura; Oliver-Martos, Begoña; De Ramón, Enrique; Luque, Gloria; Fernández, Victoria[et al.] (Sage Publications, 2010-11-18)
Background: Little is known about how the level of disability at the start of treatment with natalizumab affects its efficacy. Objectives: The aim of this study was to investigate the effect of natalizumab on relapses in ... -
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
López-Gómez, Carlos; Oliver-Martos, Begoña; Pinto-Medel, María Jesús; Suardíaz García, Margarita; Reyes-Garrido, Virginia; Urbaneja, Patricia; Fernández-Fernández, Óscar; Leyva-Fernández, Laura[et al.] (BMJ Journals, 2016)
Objective We aimed to assess the effects of interferon β (IFNβ) treatment on the expression of the splice variants of the Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors in different cell ... -
TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis
López-Gómez, Carlos; Fernández, Oscar; García-León, Juan Antonio; Pinto-Medel, María Jesús; Oliver-Martos, Begoña; Ortega-Pinazo, Jesús; Suardíaz-García, Margarita; García-Trujillo, Lucía; Guijarro-Castro, Cristina; Benito-León, Julián; Prat, Isidro; Varadé, Jezabel; Alvarez-Lafuente, Roberto; Urcelay, Elena; Leyva-Fernández, Laura[et al.] (Public Library of Science, 2011-07)
The TNF-related apoptosis inducing ligand (TRAIL)/TRAIL receptor system participates in crucial steps in immune cell activation or differentiation. It is able to inhibit proliferation and activation of T cells and to induce ...